Anbio Biotechnology Class A Ordinary Shares(NNNN)Earnings, Financials & Key Ratios
NNNN•NASDAQ
$11.90
74.4× P/E·Price updated Jul 7, 2026
AboutAnbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.Show more
- Revenue$9M+5.6%
- EBITDA$6M+124.7%
- Net Income$6M+169.9%
- EPS (Diluted)0.16+185.7%
- Gross Margin87.24%+21.3%
- EBITDA Margin66.7%+112.7%
- Operating Margin66.7%+173.6%
- Net Margin74.06%+155.5%
- ROE27.05%+82.5%
NNNN Price & Volume
Anbio Biotechnology Class A Ordinary Shares (NNNN) stock price & volume — 10-year historical chart
Loading chart...
Revenue Volatility Challenges Anbio's Asset-Light Model
Investment Thesis • Updated 2024Q4
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Fortress
Cash Flow:Mixed
Primary Risk:Revenue volatility and scale
Key Thesis Takeaways
- Anbio Biotechnology faces significant top-line instability, evidenced by a 36.0% revenue contraction in 2024Q4, which complicates the sustainability of its current diagnostic testing business model.
- While the company maintains a fortress balance sheet with $11.8M in cash and zero debt, the lack of operating leverage and erratic earnings quality suggest that current valuation multiples, such as a 68.81 P/S ratio, may be difficult to justify.
- Investors should monitor whether the firm can stabilize its cost structure and translate accounting profits into consistent cash generation, as the current reliance on working capital swings for liquidity remains a primary risk factor.
Verdict Logic
the company's erratic earnings quality, highlighted by an operating cash flow to net income ratio of -1.21 in 2024Q4, suggests that current accounting profits are not reliably translating into cash.
NNNN Growth Metrics
Anbio Biotechnology Class A Ordinary Shares (NNNN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-28.39%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-13.84%
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years31.98%
TTM-
Return on Capital
10 Years56.64%
5 Years56.64%
3 Years17.05%
Last Year24.36%
NNNN Recent Earnings
Anbio Biotechnology Class A Ordinary Shares (NNNN) EPS & revenue vs analyst estimates — last 1 quarters
Q2 2026Latest
Apr 7, 2026Metric
Actual
Est
EPS
$0.07
—
Rev
$5M
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 7, 2026 | $0.07 | $5M |
Based on last 1 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Anbio Biotechnology Class A Ordinary Shares (NNNN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $11.90 | $522.31M | 74.38 | 5.64% | 74.06% | 27.05% | — | |
| $5.00 | $2.59B | -29.41 | 40.34% | -2.58% | -17.08% | — | |
| $31.92 | $2.94B | -2.63 | 5.04% | -32.84% | -40.92% | — | |
| $17.00 | $1.16B | -1.02 | -1.89% | -45.57% | -56.31% | — | |
| $1.86 | $10.88M | -0.43 | — | — | — | — | |
| $570.25 | $45.29B | 43.60 | 10.42% | 24.63% | 70.87% | — |
Compare NNNN vs Peers
Anbio Biotechnology Class A Ordinary Shares (NNNN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when NNNN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NNNN Frequently Asked Questions
Anbio Biotechnology Class A Ordinary Shares (NNNN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Anbio Biotechnology Class A Ordinary Shares's revenue?
Anbio Biotechnology Class A Ordinary Shares (NNNN) reported $16.1M in revenue for fiscal year 2025. This represents a 264% increase from $4.4M in 2021.
How fast is Anbio Biotechnology Class A Ordinary Shares growing?
Anbio Biotechnology Class A Ordinary Shares (NNNN) grew revenue by 5.6% over the past year. This is steady growth.
Is NNNN profitable?
Yes, Anbio Biotechnology Class A Ordinary Shares (NNNN) is profitable, generating $5.0M in net income for fiscal year 2025 (74.1% net margin).
Dividend & Returns
What is NNNN's return on equity?
Anbio Biotechnology Class A Ordinary Shares (NNNN) has a return on equity (ROE) of 27.0%. This is excellent, indicating efficient use of shareholder capital.
What is Anbio Biotechnology Class A Ordinary Shares's free cash flow?
Anbio Biotechnology Class A Ordinary Shares (NNNN) generated $3.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.